Brief: Incannex Appoints Principal Investigators For IHL-42X Phase 2/3 Clinical Trial
16/06/2023 13:13
June 16 (Reuters) - Incannex Healthcare Ltd IHL.AX :
* INCANNEX APPOINTS PRINCIPAL INVESTIGATORS FOR IHL-42X
PHASE 2/3
CLINICAL TRIAL
* INCANNEX APPOINTS PRINCIPAL INVESTIGATORS FOR IHL-42X
PHASE 2/3
CLINICAL TRIAL
Source text for Eikon: ID:nGNX3f52Nw
Further company coverage: IHL.AX
(reuters.briefs@thomsonreuters.com)
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed